Adherium

Adherium is rated 3 out of 5 in the category medical devices. Read and write reviews about Adherium. Adherium (ASX.ADR) is a global leader in digital health technologies that address sub-optimal medication use in chronic disease. Its Hailie™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart"​ devices for respiratory medications globally. Adherium's Hailie™ sensors attach to prescription inhalers to provide reminders and monitoring of inhaler usage. The Hailie™ platform uses wireless communications technology to provide real time data collection and reporting from the Company's inhalers. Hailie™ technology has been independently shown to: - Increase adherence to preventative medication by 180% in children and 59% in adults; - Reduce severe exacerbations in adults by 60%; and - Contribute to significant improvements in quality of life for people with chronic asthma. The Hailie™ platform has so far been used in more than 40 projects (clinical, device validation or other). The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.